Movement disorders clinical practice · 2025
Switching from Levodopa/Carbidopa Intestinal Gel to Continuous Subcutaneous Foslevodopa/Carbidopa Infusion in Advanced Parkinson's Disease: A Case Series.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Baille Guillaume, Patte-Karsenti Nathalie, Salardaine Quentin, de Saint-Vaulry Hélène, Brandel Jean-Philippe, Desjardins Clément
Аннотация
BACKGROUND: Continuous subcutaneous foslevodopa/foscarbidopa infusion (CSFLI) is a novel non-surgical alternative to levodopa/carbidopa intestinal gel (LCIG) for advanced Parkinson's disease (aPD), but real-world switch data remain limited.
OBJECTIVES: To describe the feasibility, safety, and clinical effects of switching from LCIG to CSFLI.
METHODS: We retrospectively reviewed eight aPD patients switched from LCIG to CSFLI at a single center between November 2024 and May 2025. Motor and non-motor symptoms, quality of life, and levodopa equivalent daily doses were assessed at baseline (M0) and six months (M6).
RESULTS: Small but significant improvements occurred in UPDRS part I, III, and IV and PDQ-8 scores at M6. Total LEDD remained stable. CSFLI was well tolerated with mild local skin reactions.
CONCLUSION: Switching from LCIG to CSFLI is feasible and safe, providing stable dopaminergic delivery with modest symptomatic benefits in selected aPD patients.
OBJECTIVES: To describe the feasibility, safety, and clinical effects of switching from LCIG to CSFLI.
METHODS: We retrospectively reviewed eight aPD patients switched from LCIG to CSFLI at a single center between November 2024 and May 2025. Motor and non-motor symptoms, quality of life, and levodopa equivalent daily doses were assessed at baseline (M0) and six months (M6).
RESULTS: Small but significant improvements occurred in UPDRS part I, III, and IV and PDQ-8 scores at M6. Total LEDD remained stable. CSFLI was well tolerated with mild local skin reactions.
CONCLUSION: Switching from LCIG to CSFLI is feasible and safe, providing stable dopaminergic delivery with modest symptomatic benefits in selected aPD patients.